Status:
COMPLETED
Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada
Lead Sponsor:
AbbVie
Conditions:
Endometriosis
Eligibility:
FEMALE
18-50 years
Brief Summary
The objective of this study is to evaluate real-world effectiveness of elagolix in Canadian women with endometriosis.
Eligibility Criteria
Inclusion
- Prescribed elagolix as part of standard treatment
- Naive to elagolix prior to starting this study or have stopped taking elagolix for 2 months prior to the start of this study
- Symptomatic endometriosis (clinically or surgically diagnosed) including currently experiencing dysmenorrhea
- Has provided written informed consent allowing the use of their data for the study
Exclusion
- Did not consent
- Cannot fill out questionnaires
- Prescribed elagolix for a period of 1 or 2 months only
- Post-menopausal (naturally or surgically)
- Symptomatic uterine fibroid(s)
- Had medical treatment for uterine fibroids (any length of treatment)
Key Trial Info
Start Date :
December 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 27 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04080856
Start Date
December 4 2019
End Date
September 27 2021
Last Update
September 28 2022
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
South Health Campus Rheumatology Clinic /ID# 213065
Calgary, Alberta, Canada, T3M 1M4
2
Aubrey D. Uretsky Professional Corporation /ID# 214753
Edmonton, Alberta, Canada, T5T 1L6
3
BC Women's Hospital /ID# 214561
Vancouver, British Columbia, Canada, V6H 2N9
4
Strand Clinic /ID# 213567
St. John's, Newfoundland and Labrador, Canada, A1A 4Y3